The Lily Foundation
Private, Limited by guarantee, no share capital, use of 'Limited' exemption · Warlingham
ActiveUnited KingdomIncorporated 2007Private, Limited by guarantee, no share capital, use of 'Limited' exemption
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2022-08-31
IXBRL · 222 source facts · 19 selected values
Not assessedlegacy record
Accounts to 2022-08-31
IXBRL · 222 source facts · 19 selected values
Not assessed
legacy record
- Reporting period
- 2021-09-01 to 2022-08-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 142
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- char-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0015_06400879_20220831
- Source archive
- Accounts_Monthly_Data-May2023.zip
Accounts to 2021-08-31
IXBRL · 223 source facts · 20 selected values
Not assessedlegacy record
Accounts to 2021-08-31
IXBRL · 223 source facts · 20 selected values
Not assessed
legacy record
- Reporting period
- 2020-09-01 to 2021-08-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 145
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- char-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0106_06400879_20210831
- Source archive
- Accounts_Monthly_Data-May2022.zip
Registered details
06400879- Status
- Active
- Type
- Private, Limited by guarantee, no share capital, use of 'Limited' exemption
- Incorporated
- 2007-10-16
- Jurisdiction
- —
- Registered office
- 31, WARREN PARK, WARLINGHAM, SURREY, CR6 9LD
Classification
1 SIC codes53108
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
1 matched grantsMitoCluster: an integrated phenotyping and mouse model generation platform for mitochondrial disease and dysfunctionActiveMRC · Partnership and Contribution · 2022-03-31 – 2027-03-30 · with 7 other participants£2,172,053whole project
MitoCluster: an integrated phenotyping and mouse model generation platform for mitochondrial disease and dysfunctionActive
MRC · Partnership and Contribution · 2022-03-31 – 2027-03-30 · with 7 other participants
£2,172,053
whole project
University College LondonleadAbliva ABNanna Therapeutics LtdReneo Pharma LtdStealth BiotherapeuticsThe Lily FoundationUniversity of BristolUniversity Of Edinburgh